Patents by Inventor Pan Zheng

Pan Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes
    Publication number: 20220000974
    Abstract: Provided herein are methods and compositions for lowering low-density lipoprotein cholesterol or glucose levels, and for treating subjects with prediabetes or diabetes by targeting CD24-Siglec interactions.
    Type: Application
    Filed: February 5, 2020
    Publication date: January 6, 2022
    Inventors: Yang Liu, Pan Zheng, Xu Wang, Martin Devenport
  • Targeting CD24-Siglec Interactions for the Treatment and Prevention of Nonalcoholic Steatohepatitis
    Publication number: 20220000973
    Abstract: Provided herein are methods and compositions for the prevention and treatment of nonalcoholic steatohepatitis (NASH) by targeting the CD24-Siglec axis.
    Type: Application
    Filed: February 5, 2020
    Publication date: January 6, 2022
    Inventors: Yang Liu, Pan Zheng, Xu Wang, Mingyue Liu, Martin Devenport
  • Echinomycin formulation, method of making and method of use thereof
    Patent number: 11116726
    Abstract: A liposomal drug formulation for treating a disease in a patient characterized by overexpression of HIF-1? and/or HIF-2? includes a plurality of liposomes in a pharmaceutically acceptable carrier. The liposomes encapsulate echinomycin and are made from a peglyated phospholipid, a neutral phosphoglyceride, and a sterol. The PEGylated liposomes may be used to treat proliferative diseases, leukemia, cancer, autoimmune diseases and graft-versus-host disease.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: September 14, 2021
    Assignee: CHILDRENS RESEARCH INSTITUTE, CHILDRENS NATIONAL MEDICAL CENTER
    Inventors: Yang Liu, Yin Wang, Yan Liu, Christopher Bailey, Pan Zheng
  • METHODS OF USE OF CD24 FOR THE PREVENTION AND TREATMENT OF LEUKEMIA RELAPSE
    Publication number: 20210268061
    Abstract: The present invention relates to the use of a CD24 protein for preventing or treating relapse of a cancer in a subject. The present invention also relates to the use of a CD24 protein for reducing cancer stem cell activity.
    Type: Application
    Filed: June 3, 2019
    Publication date: September 2, 2021
    Applicants: ONCOIMMUNE, INC, UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Yang Liu, Pan Zheng, Martin Devenport
  • METHODS OF USE OF CD24 FOR THE PREVENTION AND TREATMENT OF GRAFT VERSUS HOST DISEASE AND MUCOSITIS
    Publication number: 20210228680
    Abstract: The present invention relates to the use of a CD24 protein for preventing or treating Graft versus Host Disease and mucositis.
    Type: Application
    Filed: June 3, 2019
    Publication date: July 29, 2021
    Applicant: ONCOIMMUNE, INC
    Inventors: Yang Liu, Pan Zheng, Martin Devenport
  • ANTI-CD24 COMPOSITIONS AND USES THEREOF
    Publication number: 20210214458
    Abstract: Provided herein are anti-CD24 antibodies that selectively bind human CD24 expressed in cancer cells, but not human CD24 expressed in non-cancerous cells, and the use of such antibodies in cancer therapy.
    Type: Application
    Filed: May 13, 2019
    Publication date: July 15, 2021
    Applicants: ONCOIMMUNE, INC, CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang Liu, Pan Zheng, Rhonda Flores, Hung-Yen Chou, Zhihong Xue, Peiying Ye, Martin Devenport
  • Use of CD24 for lowering low-density lipoprotein cholesterol levels
    Patent number: 11026995
    Abstract: The present invention relates to the use of a CD24 protein for lowering low-density lipoprotein cholesterol levels, treating and preventing atherosclerosis, and for reducing risk of cardiovascular disease.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: June 8, 2021
    Assignee: ONCOIMMUNE, INC.
    Inventors: Yang Liu, Pan Zheng
  • USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS
    Publication number: 20210161991
    Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
    Type: Application
    Filed: October 13, 2020
    Publication date: June 3, 2021
    Applicant: OncoImmune, Inc.
    Inventors: Yang LIU, Yin WANG, Yan LIU, Sami N. MALEK, Pan ZHENG
  • Use of CD24 Proteins for Treating Leptin-Deficient Conditions
    Publication number: 20210162006
    Abstract: This invention relates to the use of a CD24 protein for treating leptin-deficient conditions, such as lipodystrophy, by increasing the level of circulating leptin.
    Type: Application
    Filed: October 12, 2020
    Publication date: June 3, 2021
    Applicant: ONCOIMMUNE, INC.
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT
  • METHODS OF SELECTING AND DESIGNING SAFER AND MORE EFFECTIVE ANTI-CTLA-4 ANTIBODIES FOR CANCER THERAPY
    Publication number: 20210047410
    Abstract: The present invention relates to compositions of anti-CTLA-4 antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for the reduction of autoimmune side effects compared to other immunotherapeutic agents.
    Type: Application
    Filed: January 29, 2019
    Publication date: February 18, 2021
    Applicants: Oncolmmune, Inc., Children's Research Institute, Children's National Medical Center
    Inventors: Yang Liu, Pan Zheng, Fei Tang, Mingyue Liu, Martin Devenport, Xuexiang Du, Yan Zhang
  • MUTANT ANTI-CTLA-4 ANTIBODIES WITH IMPROVED IMMUNOTHERAPEUTIC EFFECT BUT ATTENUATED ADVERSE EFFECTS
    Publication number: 20210040212
    Abstract: This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.
    Type: Application
    Filed: January 29, 2019
    Publication date: February 11, 2021
    Applicants: Oncolmmune, Inc., University of Maryland, Baltimore
    Inventors: Yang Liu, Pan Zheng, Fei Tang, Mingyue Liu, Martin Devenport, Xuexiang Du, Yan Zhang
  • METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS
    Publication number: 20200399345
    Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Application
    Filed: September 1, 2020
    Publication date: December 24, 2020
    Applicant: OncoImmune, Inc.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • Use of CD24 proteins for treating leptin-deficient conditions
    Patent number: 10799558
    Abstract: This invention relates to the use of a CD24 protein for treating leptin-deficient conditions, such as lipodystrophy, by increasing the level of circulating leptin.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: October 13, 2020
    Assignee: ONCOIMMUNE, INC.
    Inventors: Yang Liu, Pan Zheng, Martin Devenport
  • Methods of use of soluble CD24 for therapy of rheumatoid arthritis
    Patent number: 10793617
    Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: October 6, 2020
    Assignee: ONCOIMMUNE, INC.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • Chimeric and Humanized Anti-Human CTLA4 Monoclonal Antibodies and Uses Thereof
    Publication number: 20200283526
    Abstract: This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.
    Type: Application
    Filed: February 27, 2020
    Publication date: September 10, 2020
    Applicant: ONCOIMMUNE, INC.
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT
  • METHODS OF USE OF SOLUBLE CD24 FOR TREATING IMMUNE RELATED ADVERSE EVENTS IN CANCER THERAPIES
    Publication number: 20200197485
    Abstract: The present invention relates to a CD24 protein for treating immune-related adverse events (irAEs) associated with cancer immunotherapy. Provided herein is a method of treating, mitigating, minimizing, or preventing immunerelated adverse events (irAEs) associated with a cancer immunotherapy by administering a CD24 protein to a subject in need thereof. The irAE may be diarrhea or another gastrointestinal disorder, pure red cell aplasia, microcytic anemia, lupus, autoimmune nephritism, autoimmune hepatitis, pneumonitis, myocarditis, pericarditis, endocrinopathy, Addison's disease, hypogonadism, Sjogren's syndrome, or type I diabetes. The CCD24 protein may comprise a mature human CD24 or a variant thereof.
    Type: Application
    Filed: May 21, 2018
    Publication date: June 25, 2020
    Applicants: ONCOIMMUNE, INC., CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT
  • METHODS OF USE OF SOLUBLE CD24 FOR NEUROPROTECTION AND REMYELINATION
    Publication number: 20200181235
    Abstract: The present invention relates to compositions and their use in methods of protecting and maintaining oligodendrocytes, and of treating demyelinating disorders
    Type: Application
    Filed: May 15, 2018
    Publication date: June 11, 2020
    Applicants: ONCOIMMUNE, INC., CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT, Ning LI
  • COMPOSITIONS COMPRISING APTAMERS AND NUCLEIC ACID PAYLOADS AND METHODS OF USING THE SAME
    Publication number: 20200171068
    Abstract: The disclosure relates to compositions comprising a nucleic acid sequence having two domains: a cell targeting domain and a microRNA domain, wherein the cell targeting domain comprises an aptamer sequence that targets cancer cells and the microRNA domain comprises a microRNA sequence that binds to an endogenous mRNA sequence within a cancer cell and disrupts normal function of the cell.
    Type: Application
    Filed: May 18, 2018
    Publication date: June 4, 2020
    Applicant: Children's National Medical Center
    Inventors: Yang Liu, Pan Zheng, Toshihiko Tanno
  • USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS
    Publication number: 20200147167
    Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
    Type: Application
    Filed: January 21, 2020
    Publication date: May 14, 2020
    Applicant: OncoImmune, Inc.
    Inventors: Yang LIU, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
  • Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
    Patent number: 10618960
    Abstract: This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: April 14, 2020
    Assignee: ONCOIMMUNE, INC.
    Inventors: Yang Liu, Pan Zheng, Martin Devenport